Moreover, various alternative approaches for the treatment of pancreatic cancer are being explored to establish new treatment options and therapeutics i.e., gentamicin in combination with immunotherapy (a monoclonal antibody against CD40) [58] or metabolic inhibitor CPI-613 (Devimistad) [59]. This evidence concerns the gene CD40 and pancreatic neoplasm.